Unfortunately people want drama and the media will gladly manufacture it. Religion was supposed to be the opiate of the masses, now it is drama and reality shows.
I like there technology and management, but I am gun shy buying at these levels. BLUE is supposed to update sickle trials this month and I am not sure if we will see a big drop before then, unless there is bad news forthcoming.
I recall you from the NPS board (yay us longs), I rolled some of my NPS profits into BLUE. Your posts there were cogent and informed. Any thoughts? I haver been holding BLUE since $90.
thx in advance
All these companies have issued long term debt to fund medical expenese for smoking related illness at the state level. Some states securitized the bonds, some did not, therefore they are tied to these companies for many years to come and need the money these bonds provide. They don't like them until they need them.
This was at about $20 on Jauary 6 and now it is almost $40. I would say there must be a something brewing, but why do an offering, unless they do not want to sell?
Morgan execised its option to purcahse additional shares...they must believe in this. I am still holding with a basis of about $7.00.
I am in at an average basis of $7 / share so I can weather the ups and downs. I was in on NPS at about the same price and road that one to the Shire buy-out @ $46. NBIX needs a couple pipeline candidates to get FDA approval. Since Abbvie is a partner on Elgalolix and Abbvie needs to supplement its pipeline, that would be my first guess at a possible suitor. Buyout price, if there is one, depends on the market for the products and potential pricing of the products.
You need to look at the price arbitrage and factor in the tax implications since this is a taxable transaction.
*DJ AbbVie Says Results From Second Phase 3 Trial Expected in Late 2015 NBIX
Jan 08, 2015 08:00:00 (ET)
(MORE TO FOLLOW) Dow Jones Newswires (212-416-2800)
January 08, 2015 08:01 ET (13:01 GMT)
A negative article by "The Street" is not surprising. I was expecting a negagtive "Street" article and Feuerstein to pen the article himself, not one of his lackeys. Hold on, this is worth $50+ IMHO.
dmal - I have been on this board since 2012 and there are a number of people who have been on this board, probably longer than me, who post links / cites / actual news. I try to do as they do and provided concrete information to spur thoughtful dialogue.
Its a shame though, not 6 months ago Nader said we were not for sale. I was hoping he meant it.
Best of luck in your investments.
13:13 EST - The auction for rare disease drug maker NPS Pharmaceuticals (NPSP) is off to a fast start. First-round, non-binding bids for the company are due on Friday, according to a person briefed on the matter. On Monday, The Wall Street Journal reported that NPS is working with investment bank Goldman Sachs to run an auction for the Bedminster, N.J.-based company. Dublin-based Shire PLC has in the past expressed interest in NPS, and strategic bidders are likely to kick the company's tires. NPSP shares were up 2.2% to $39, adding to Monday's 6.6% gains following the WSJ report. (email@example.com; @DanaMattioli)